LN 144

Drug Profile

LN 144

Alternative Names: Autologous T-cell therapy - Lion Biotechnologies; Contego; LN144; TILs - Lion Biotechnologies; Tumour infiltrating lymphocytes - Lion Biotechnologies

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Lion Biotechnologies Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 20 Dec 2016 Lion Biotechnologies and H. Lee Moffitt Cancer Center and Research Institute enter into clinical trial agreement
  • 20 Dec 2016 Lion Biotechnologies in collaboration with H. Lee Moffitt Cancer Center and Research Institute initiates a clinical trial for Malignant-melanoma (Metastatic) before December 2016
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, First-line therapy, Metastatic disease) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top